Skip to main content
. 2013 Nov 5;1(1):552–565. doi: 10.1016/j.redox.2013.10.008

Fig. 8.

Fig. 8

A p38MAPK inhibitor and a JNK inhibitor decrease 3-MA enhanced AA cytotoxicity. E47 cells were treated with 45 µM AA plus 3-MA or rapamycin in the presence or absence of SB203580 (5 µM) or SP600125 (2.5 µM) for 24 and 48 h. (A): cell viability was determined by a MTT assay (⁎, #P<0.05 compared with AA plus 3-MA for 24 or 48 h, N=3). (B) and (C): Effects of SB201580 and SP600125 on the activation of p38 MAPK. The inhibition of p38 MAPK by SB203580 at 24 h (B) and 48 h (C) was determined by Immunoblot analyses. The pp38 MAPK/p38 MAPK ratios are listed underneath the blots (⁎P<0.05 compared with AA plus 3MA, n=3). The inhibition of JNK activation by SP600125 at 24 h (D) and 48 h (E) was determined by immunoblot analyses. The ratios of pJNK/JNK are listed at the bottom of the blots. (⁎⁎P<0.05 compared with AA plus rapamycin; ⁎P<0.05 compared with AA plus 3-MA, n=3).